Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT). Tissue specimens from both the primary tumor and pelvic lymph nodes dissected during surgery from patients with newly-diagnosed high-risk prostate cancer (PCa) will be used for the histopathology assessments. Approximately 195 participants will be enrolled to ensure that at least 156 participants complete the [18F]CTT1057 PET/CT scan procedure (i.e. investigational imaging agent administration and successful completion of the PET/CT scan), which will be required for the calculation of the co-primary endpoints.

Clinical Trial Description

This is a multi-center, single-arm, open-label prospective study to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors, using histopathology as SoT. Tissue specimens from both the primary tumor and pelvic lymph nodes dissected during surgery from patients with newly-diagnosed high-risk PCa will be used for the histopathology assessments. All participants will receive [18F]CTT1057 for PET/CT scan imaging, and surgery (radical prostatectomy and extended pelvis lymph node dissection) will be performed up to 6 weeks after [18F]CTT1057 PET for pathology assessment of the tissue specimens. The co-primary endpoints of patient-level sensitivity and region-level specificity will be assessed by comparing the central reading results of the [18F]CTT1057 PET scan to the histopathology results in the dissected tissue specimens, i.e. both the primary tumor and the dissected Pelvic Lymph Node (PLN)). Pathology will be assessed by the local pathologists as per Standard of Care (SoC), who will be blinded to the PET data. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04838626
Study type	Interventional
Source	Novartis
Contact	Novartis Pharmaceuticals
Phone	1-888-669-6682
Email	[email protected]
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	September 7, 2021
Completion date	February 24, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04081636` - Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications	N/A
Completed	`NCT03177759` - Living With Prostate Cancer (LPC)
Recruiting	`NCT04400656` - PROState Pathway Embedded Comparative Trial
Completed	`NCT02282644` - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry	N/A
Recruiting	`NCT03101176` - Multiparametric Ultrasound Imaging in Prostate Cancer	N/A
Completed	`NCT03290417` - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer	N/A
Active, not recruiting	`NCT00341939` - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed	`NCT01497925` - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT03679819` - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Active, not recruiting	`NCT03554317` - COMbination of Bipolar Androgen Therapy and Nivolumab	Phase 2
Completed	`NCT03271502` - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy	N/A
Active, not recruiting	`NCT00499421` - Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy
Not yet recruiting	`NCT04887935` - Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer	Phase 1
Not yet recruiting	`NCT05035732` - RRPC Axumin PETMRI	N/A
Not yet recruiting	`NCT05033301` - Evaluating the Effectiveness of the Nurse Ned Clinic	N/A
Not yet recruiting	`NCT04838613` - Study of Diagnostic Performance of [18F]CTT1057 in BCR	Phase 3
Not yet recruiting	`NCT04925180` - A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
Not yet recruiting	`NCT04905069` - Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy	N/A
Recruiting	`NCT03668652` - Focal Prostate Ablation Versus Radical Prostatectomy	N/A
Completed	`NCT01943500` - Collection of Blood Specimens for Circulating Tumor Cell Analysis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection — GuideView

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms